These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29283058)

  • 1. Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy.
    Ren YB; Sun SJ; Han SY
    Curr Pharm Des; 2018; 24(1):78-83. PubMed ID: 29283058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk and solutions to chimeric antigen receptor-engineered T cell-based cancer immunotherapy].
    Zhang MM; Jia DF; Diao Y
    Yao Xue Xue Bao; 2016 Jul; 51(7):1032-8. PubMed ID: 29896949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns.
    Resetca D; Neschadim A; Medin JA
    J Immunother; 2016 Sep; 39(7):249-59. PubMed ID: 27488725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming the toxicity hurdles of genetically targeted T cells.
    Casucci M; Hawkins RE; Dotti G; Bondanza A
    Cancer Immunol Immunother; 2015 Jan; 64(1):123-30. PubMed ID: 25488419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
    Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
    Front Immunol; 2021; 12():658753. PubMed ID: 33859650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
    Yang QY; Yang JD; Wang YS
    Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
    Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
    Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
    Liu J; Zhou G; Zhang L; Zhao Q
    Front Immunol; 2019; 10():456. PubMed ID: 30941126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming key challenges in cancer immunotherapy with engineered T cells.
    Arcangeli S; Mestermann K; Weber J; Bonini C; Casucci M; Hudecek M
    Curr Opin Oncol; 2020 Sep; 32(5):398-407. PubMed ID: 32796230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically engineered T cells for the treatment of cancer.
    Essand M; Loskog AS
    J Intern Med; 2013 Feb; 273(2):166-81. PubMed ID: 23198862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects.
    Ercilla-Rodríguez P; Sánchez-Díez M; Alegría-Aravena N; Quiroz-Troncoso J; Gavira-O'Neill CE; González-Martos R; Ramírez-Castillejo C
    Front Immunol; 2024; 15():1333150. PubMed ID: 39091493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
    Rath JA; Arber C
    Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
    Lin C; Zhang J
    Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy.
    Bedoya F; Frigault MJ; Maus MV
    Mol Ther; 2017 Feb; 25(2):314-320. PubMed ID: 28153085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.